Clinical experience of a tricomponent acellular pertussis vaccine combined with diphtheria and tetanus toxoids for primary vaccination in 22,505 infants.
OBJECTIVE
To assess the safety and tolerability of 12 lots of SmithKline Beecham Biologicals' diphtheria-tetanus-tricomponent acellular pertussis vaccine (DTaP) in a large cohort of 22,000 vaccinees, with detailed analyses of reactivity, immunogenicity, and immune response to pertussis toxin in subsets.


METHODS
In a prospective, double-blind, multicenter trial in Germany, 22,505 healthy infants received three vaccinations of DTaP at age 3, 4, and 5 months. Serious adverse events were followed for 1 month after each vaccination, and neurologic events for 1 year or longer. Serum IgG antibodies were assayed before vaccination and 1 month after vaccination.


RESULTS
After 67,000 doses, 153 serious adverse events (0.23%) were reported, 8 considered possibly related, and 5 related to vaccination, including 1 hypotonic-hyporesponsive episode. Incidence rates of sudden infant death syndrome (7; 0.01%) or acute neurologic events (20; 0.030%) were no higher than expected and not considered to be related to vaccination. Redness and swelling of 20 mm or greater occurred after 44 (0.6%) and 40 (0.6%) of the 7270 doses, respectively, and high fever (> 39.5 degrees C) in 6 (0.08%) subjects within 48 hours of vaccination. In the immunogenicity analysis of 580 infants, 98% responded to pertussis toxin, 96% to filamentous hemagglutinin, and 98% to pertactin. In an additional 5712 infants, the response rate to pertussis toxin was 99%.


CONCLUSIONS
In a large cohort of 22,505 infants vaccinated, SmithKline Beecham Biologicals' tricomponent DTaP vaccine was shown to be safe, well-tolerated, and immunogenic for all component antigens.
Children's Hospital, Johannes Gutenberg University, Mainz, Germany.
H J
HJ
Schmitt
A
A
Schuind
M
M
Knuf
K
K
Beutel
H
H
Schulte-Wissermann
M
M
Gahr
R
R
Schult
J
J
Folkens
W
W
Rauh
H
H
Bogaerts
H L
HL
Bork
R
R
Clemens
D015721:Diphtheria-Tetanus-Pertussis Vaccine / Q000009:adverse effects* / Q000276:immunology*; D004311:Double-Blind Method; D004827:Epilepsy; D005334:Fever; D005858:Germany; D006801:Humans; D015994:Incidence; D007223:Infant; D011446:Prospective Studies; D012640:Seizures; D013036:Spasms, Infantile; D013398:Sudden Infant Death
D015721:Diphtheria-Tetanus-Pertussis Vaccine